S. 1097 · 119th Congress

Interagency Patent Coordination and Improvement Act of 2025

Introduced on Mar 24, 2025 by Richard J. Durbin (D-IL). 4 cosponsors, 2 of them from another party. Latest action (Apr 10, 2025): Placed on Senate Legislative Calendar under General Orders. Calendar No. 41.

Stage
Reported by committee
Introduced
Mar 24, 2025
Cosponsors
4
2 from the other party
Policy area
Commerce
Open in the Congress explorerCongress.govAlert me

Progress

The furthest stage the measure reached. Simple and concurrent resolutions do not go to the President.

  1. Introduced
  2. Reported by committee
  3. 3Passed one chamber
  4. 4Passed both chambers
  5. 5Sent to the President
  6. 6Became law

Official title

A bill to amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes.

Subjects

  • Drug safety, medical device, and laboratory regulation
  • Food and Drug Administration (FDA)
  • Intellectual property
  • Intergovernmental relations

Summary

By the Congressional Research Service (Introduced in Senate, Mar 24, 2025). Public domain.

Interagency Patent Coordination and Improvement Act of 2025

This bill establishes the Interagency Task Force on Patents to support coordination and communication between the U.S. Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA) on activities relating to patents for human drugs and biological products.

The task force's duties shall include sharing information about (1) the processes of each agency, including how each agency evaluates applications (e.g., patent applications at the USPTO and new drug applications at the FDA); and (2) new approvals of patents, human drugs, biological products, and new technologies. The task force must also establish a process that requires (1) the USPTO to request from the FDA information relating to certain patent applications to help patent examiners carry out their duties, (2) the FDA to provide such information to the USPTO, and (3) the USPTO to assist the FDA in its ministerial role of listing patents.

Sponsor and cosponsors

Cosponsors by party as of the day they signed on. Original cosponsors signed on the day of introduction.

Richard J. DurbinD-ILSponsor

Democrats · 2

Republicans · 2

Roll calls

Recorded votes on the measure. Most measures move by voice vote or unanimous consent, which record no individual positions.

No recorded roll call on this measure: it moved by voice vote or unanimous consent, or has not reached the floor.

History

Every action as published, oldest first. Roll calls link to how each member voted.

  1. Mar 24, 2025Introduced in Senate
  2. Mar 24, 2025 · SenateRead twice and referred to the Committee on the Judiciary. (text: CR S1804-1805)
  3. Apr 3, 2025 · SenateCommittee on the Judiciary. Ordered to be reported with amendments favorably.
  4. Apr 10, 2025Committee on the Judiciary. Reported by Senator Grassley with amendments. Without written report.
  5. Apr 10, 2025 · SenateCommittee on the Judiciary. Reported by Senator Grassley with amendments. Without written report.
  6. Apr 10, 2025 · SenatePlaced on Senate Legislative Calendar under General Orders. Calendar No. 41.

Committees

Committees and subcommittees the measure was referred to.

Agencies in its committees' jurisdiction

Analisa's mapping of committee jurisdiction to federal agencies; the bill may touch others, or none of these.

Who lobbied on it

Organizations whose lobbying reports (LD-2) name this measure. Spending is what they reported for those quarters on all issues, not on this measure alone.

  1. PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA16 reports
    $57.5M reported (all issues)
  2. COUNCIL FOR INNOVATION PROMOTION (C4IP)12 reports
    $500K reported (all issues)
  3. AMERICAN INTELLECTUAL PROPERTY LAW ASSOCIATION (AIPLA)6 reports
    $60K reported (all issues)
  4. Campaign for Sustainable Drug Pricing (CSRxP)6 reports
    $300K reported (all issues)
  5. JOHNSON & JOHNSON SERVICES, INC.6 reports
    $13.3M reported (all issues)
  6. NOVARTIS CORPORATION6 reports
    $13.1M reported (all issues)Federal contractor: NOVARTIS PHARMACEUTICALS CORPORATION$36.2M in contracts, FY2026AI match · 100%
  7. TEVA PHARMACEUTICALS USA, INC.6 reports
    Federal contractor: TEVA PHARMACEUTICALS USA, INC.$25.9M in contracts, FY2026AI match · 100%
  8. The Campaign for Sustainable Rx Pricing6 reports
    $540K reported (all issues)
  9. BIOTECHNOLOGY INNOVATION ORGANIZATION5 reports
    $7.7M reported (all issues)
  10. Blue Cross and Blue Shield Association5 reports
    $6.3M reported (all issues)
  11. Blue Cross and Blue Shield of Florida, Inc.5 reports
    $500K reported (all issues)
  12. GSK (fka GLAXOSMITHKLINE INC.)5 reports
    $5.7M reported (all issues)
  13. ASSOCIATION OF THE UNITED STATES ARMY, (INC.)4 reports
    $408.8K reported (all issues)Federal contractor: THE ASSOCIATION OF THE UNITED STATES ARMY$20K in contracts, FY2026AI match · 100%
  14. BCBSM, Inc.4 reports
    $118K reported (all issues)
  15. Families USA Foundation, Inc.4 reports
    $38K reported (all issues)
  16. GUIDEWELL MUTUAL HOLDING CORPORATION4 reports
    $30K reported (all issues)
  17. ASSOCIATION FOR ACCESSIBLE MEDICINES3 reports
    $2.1M reported (all issues)
  18. INTELLECTUAL PROPERTY OWNERS ASSOCIATION3 reports
    $140K reported (all issues)
  19. KAISER FOUNDATION HEALTH PLAN INC.3 reports
    $1.6M reported (all issues)Federal contractor: KAISER FOUNDATION HEALTH PLAN OF WASHINGTONAI match · 97%
  20. AARP2 reports
    $11.8M reported (all issues)
  21. PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION2 reports
    $6.3M reported (all issues)
  22. SMALL BUSINESS & ENTREPRENEURSHIP COUNCIL (SBE COUNCIL)2 reports
    $105K reported (all issues)
  23. BLUE CROSS AND BLUE SHIELD OF KANSAS, INC.1 report
    $10K reported (all issues)
  24. Blood Cancer United (FKA The Leukemia & Lymphoma Society)1 report
    $590K reported (all issues)
  25. Fresenius Kabi USA LLC1 report
    $340K reported (all issues)Federal contractor: FRESENIUS KABI USA, LLCAI match · 100%

Reports filed in 2025, 2026.

Sources and method

Every figure on this page traces to these records.

  • Bill status: bills and resolutions, sponsors, actions, subjects and CRS summaries (U.S. Government Publishing Office (GovInfo), from Congress.gov (Library of Congress))GovInfo Bill Status bulk data (Congress.gov; summaries by the Congressional Research Service) · data current to Oct 10, 2026 · loaded Oct 10, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Members of Congress, their terms, committees and identifiers (The @unitedstates project (from the Biographical Directory of the U.S. Congress, the House and the Senate))unitedstates/congress-legislators: legislators, committees and current committee membership · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: CC0 1.0 (public domain dedication)
  • House roll-call votes (Office of the Clerk, U.S. House of Representatives)Office of the Clerk, U.S. House of Representatives, roll-call vote records · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Senate roll-call votes and DW-NOMINATE scores (Voteview (UCLA Department of Political Science))Lewis, Jeffrey B., Keith Poole, Howard Rosenthal, Adam Boche, Aaron Rudkin, and Luke Sonnet (2026). Voteview: Congressional Roll-Call Votes Database. https://voteview.com/ · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Free to use with the required citation
  • Lobbying disclosures (LD-1 registrations, LD-2 quarterly reports, LD-203 contribution reports) (Clerk of the U.S. House of Representatives)Clerk of the House, Lobbying Disclosure Act filings (organizations only; lobbyists' names are not loaded) · data current to Oct 10, 2026 · loaded Oct 10, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Positions are shown only where a roll call recorded them; voice votes and unanimous consent record none.
  • Money and votes are shown side by side; neither explains the other.